Terms: = Ovarian cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
56 results:
1. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
2. Morphological Changes of the ovarian Vein in Pelvic Venous Disorders.
Nykonenko A; Trailin A; Lazarashvili Z; Proczka RM; Havrylenko B; Nykonenko O
Eur J Vasc Endovasc Surg; 2024 Mar; 67(3):500-505. PubMed ID: 37952635
[TBL] [Abstract] [Full Text] [Related]
3.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract] [Full Text] [Related]
4. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract] [Full Text] [Related]
5. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
6. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract] [Full Text] [Related]
7. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
[TBL] [Abstract] [Full Text] [Related]
8. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract] [Full Text] [Related]
9. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring
Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F
J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840
[TBL] [Abstract] [Full Text] [Related]
10. Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology.
Kuriyama S; Yano M; Kusaba T; Zaitsu S; Nishida H; Yasuda M; Nasu K
Med Mol Morphol; 2023 Mar; 56(1):20-27. PubMed ID: 36183278
[TBL] [Abstract] [Full Text] [Related]
11. ccne1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma.
Mei J; Tian H; Huang HS; Wu N; Liou YL; Chu TY; Wang J; Zhang W
Cell Cycle; 2023 Jan; 22(1):85-99. PubMed ID: 36004387
[TBL] [Abstract] [Full Text] [Related]
12. Multiomic Characterization of High-Grade Serous ovarian Carcinoma Enables High-Resolution Patient Stratification.
Hollis RL; Meynert AM; Michie CO; Rye T; Churchman M; Hallas-Potts A; Croy I; McCluggage WG; Williams ARW; Bartos C; Iida Y; Okamoto A; Dougherty B; Barrett JC; March R; Matakidou A; Roxburgh P; Semple CA; Harkin DP; Kennedy R; Herrington CS; Gourley C
Clin Cancer Res; 2022 Aug; 28(16):3546-3556. PubMed ID: 35696721
[TBL] [Abstract] [Full Text] [Related]
13. ccne1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract] [Full Text] [Related]
14. WEE1i-ATRi combination therapy: a promising low-dose treatment for
Goehring L; Huang TT
Cell Rep Med; 2021 Sep; 2(9):100402. PubMed ID: 34622238
[No Abstract] [Full Text] [Related]
15. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
[TBL] [Abstract] [Full Text] [Related]
16. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
17. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
Sokolenko AP; Gorodnova TV; Bizin IV; Kuligina ES; Kotiv KB; Romanko AA; Ermachenkova TI; Ivantsov AO; Preobrazhenskaya EV; Sokolova TN; Broyde RV; Imyanitov EN
Cancer Chemother Pharmacol; 2021 Sep; 88(3):439-450. PubMed ID: 34080040
[TBL] [Abstract] [Full Text] [Related]
18.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract] [Full Text] [Related]
19. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Do KT; Manuszak C; Thrash E; Giobbie-Hurder A; Hu J; Kelland S; Powers A; de Jonge A; Shapiro GI; Severgnini M
Cancer Immunol Immunother; 2021 Oct; 70(10):2991-3000. PubMed ID: 33745032
[TBL] [Abstract] [Full Text] [Related]
20. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract] [Full Text] [Related]
[Next]
